Registration Dossier

Toxicological information

Endpoint summary

Currently viewing:

Administrative data

Description of key information

Key value for chemical safety assessment

Repeated dose toxicity: via oral route - systemic effects

Link to relevant study records
Reference
Endpoint:
sub-chronic toxicity: oral
Type of information:
experimental study
Adequacy of study:
key study
Reliability:
2 (reliable with restrictions)
Qualifier:
equivalent or similar to guideline
Guideline:
OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
GLP compliance:
not specified
Species:
rat
Details on oral exposure:
4 months
Remarks:
Doses / Concentrations:10 mg/kgBasis:no data
Dose descriptor:
LOAEL
Effect level:
10 mg/kg bw/day (actual dose received)
Basis for effect level:
other: see 'Remark'
Critical effects observed:
not specified
Conclusions:
Findings were included central nervous system, liver and spleen effects.
Endpoint conclusion
Endpoint conclusion:
adverse effect observed
Dose descriptor:
LOAEL
10 mg/kg bw/day
Study duration:
chronic
Species:
rat

Repeated dose toxicity: inhalation - systemic effects

Link to relevant study records
Reference
Endpoint:
short-term repeated dose toxicity: inhalation
Type of information:
experimental study
Adequacy of study:
key study
Reliability:
2 (reliable with restrictions)
Qualifier:
equivalent or similar to guideline
Guideline:
OECD Guideline 412 (Subacute Inhalation Toxicity: 28-Day Study)
GLP compliance:
not specified
Species:
dog
Strain:
Beagle
Sex:
male
Route of administration:
inhalation: aerosol
Type of inhalation exposure:
whole body
Vehicle:
air
Analytical verification of doses or concentrations:
yes
Duration of treatment / exposure:
30-day
Frequency of treatment:
6 hrs daily, 5 days a week for a total of 20 exposures in 1 month
Remarks:
Doses / Concentrations:100 mg/m3Basis:nominal conc.
Remarks:
Doses / Concentrations:800 mg/m3Basis:nominal conc.
No. of animals per sex per dose:
2
Control animals:
yes
Dose descriptor:
LOEC
Effect level:
100 mg/m³ air (nominal)
Based on:
test mat.
Sex:
male
Basis for effect level:
other: Hepatotoxic effects
Critical effects observed:
not specified
Conclusions:
The results of this study indicate that potassium amyl xanthate has an adverse effect on the the liver in dogs. There were no treatment-related changes in the haematological or urinalysis values in any of the animals.
Endpoint conclusion
Endpoint conclusion:
adverse effect observed
Dose descriptor:
LOAEC
100 mg/m³
Study duration:
subacute
Species:
dog
Quality of whole database:
Inhalation of potassium amyl xanthate produces adverse effects in the livers of dogs.

Repeated dose toxicity: inhalation - local effects

Endpoint conclusion
Endpoint conclusion:
no adverse effect observed

Repeated dose toxicity: dermal - systemic effects

Endpoint conclusion
Endpoint conclusion:
no study available

Repeated dose toxicity: dermal - local effects

Endpoint conclusion
Endpoint conclusion:
no study available

Additional information

In the absence of reliable information, the data forpotassium amyl xanthate (CAS# 2720-73-2) may be used as a surrogate for sodium ethyl xanthate (CAS# 140-90-9).

The target sites for sodium ethyl xanthate, and other xanthates are the central nervous system, liver and kidneys. The adverse effects seen in the toxicity studies could be due to the xanthates (such as sodium ethyl xanthate), their decomposition products or a combination of both.

There is no human information available concerning reproductive toxicity for xanthates(, CHEMINFO ,2004, ,Chemical Profiles Created by CCOHS , www.ccohs.ca).


Repeated dose toxicity: via oral route - systemic effects (target organ) cardiovascular / hematological: other; neurologic: central nervous system

Repeated dose toxicity: inhalation - systemic effects (target organ) digestive: liver

Justification for classification or non-classification